Pagari Life Science

Executive Summary

Pagari Life Science Corp. is a private biotech company headquartered in San Diego, California, founded in 2020. The company is developing a novel platform of small molecule therapeutics focused on anti-herpetic applications and advanced wound healing. Its mission is to deliver treatments that heal faster, eliminate pain, and are safe, non-addictive, and effective. Pagari's approach targets significant unmet medical needs in herpes simplex virus infections and chronic wound management, where current therapies often have limited efficacy, side effects, or risk of addiction. The platform leverages proprietary small molecules designed to interfere with viral replication and promote tissue regeneration. While the company is in early preclinical stages, its dual focus on antiviral and wound healing addresses large and growing markets. The herpes treatment market alone is valued at over $3 billion annually, and advanced wound care products represent a multi-billion-dollar opportunity. Pagari's success hinges on demonstrating proof-of-concept in animal models and progressing towards an Investigational New Drug (IND) application. As a private entity, the company has not disclosed funding or valuation, but its novel approach and experienced leadership team position it as a potential emerging player in the small molecule therapeutics space.

Upcoming Catalysts (preview)

• Q4 2026Preclinical efficacy data release for lead anti-herpetic candidate40% success
• 2027IND filing for lead wound healing candidate30% success
• Q2 2026Strategic partnership or licensing agreement20% success